This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Informatics/ Internet in Medicine  • Internet  • Women's Health  • Pregnancy and Breast Feeding  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2003;289:1624.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A comprehensive information resource about exposure to diethylstilbestrol (DES) is now available on the Internet for clinicians, consumers, and others (http://www.cdc.gov/DES). The resource, "DES Update," was launched in March by the Centers for Disease Control and Prevention (CDC).

DES is a synthetic estrogen first prescribed in 1938 for women who experienced miscarriages or premature deliveries. Prescriptions for pregnant women were banned in 1971 by the Food and Drug Administration after research linked DES to a rare vaginal cancer, clear cell adenocarcinoma, in female offspring (N Engl J Med. 1971;284:878-881).

Diethylstilbestrol

An estimated 5 to 10 million individuals (mothers and their newborns) were exposed to DES between 1938 and 1971. Subsequent research has identified additional health risks: women who were prescribed DES while pregnant have a modestly increased risk for breast cancer. In addition to clear cell adenocarcinoma of the vagina and cervix, "DES daughters" who . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?